33, 45 Here, we extend these studies by showing that ibrutinib disrupted BCR and NF-κB signaling pathways in xenografted CLL cells in the spleen microenvironment in vivo and selectively reduced proliferation of the tumor cells but not of T-cells. The gene discussed is BCR; the disease is neoplasm.